var data={"title":"Edetate calcium disodium (calcium EDTA): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Edetate calcium disodium (calcium EDTA): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6090?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=edetate-calcium-disodium-calcium-edta-patient-drug-information\" class=\"drug drug_patient\">see &quot;Edetate calcium disodium (calcium EDTA): Patient drug information&quot;</a> and <a href=\"topic.htm?path=edetate-calcium-disodium-calcium-edta-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Edetate calcium disodium (calcium EDTA): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708725\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cerebral edema:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Edetate calcium disodium is capable of producing toxic effects that can be fatal. Lead encephalopathy is relatively rare in adults, but occurs more often in pediatric patients in whom it may be incipient and thus overlooked. The mortality rate in pediatric patients has been high. Patients with lead encephalopathy and cerebral edema may experience a lethal increase in intracranial pressure following, intravenous (IV) infusion; the intramuscular (IM) route is preferred for these patients. In cases where the IV route is necessary, avoid rapid infusion. The dosage schedule should be followed and at no time should the recommended daily dose be exceeded.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164152\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Chelating Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164145\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lead poisoning:</b> <b>Note:</b> Available guidelines recommend chelation therapy with blood lead levels &gt;50 mcg/dL and significant symptoms; chelation therapy may also be indicated with blood lead levels &ge;100 mcg/dL and/or symptoms (Kosnett 2007). Depending upon the blood lead level, additional courses may be necessary; at least 2 to 4 days should elapse before repeat treatment is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Blood lead levels &lt;70 mcg/dL and asymptomatic:</i> IM, IV: 1000 mg/m<sup>2</sup>/day for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Blood lead levels &ge;70 mcg/dL or symptomatic lead poisoning (in conjunction with dimercaprol):</i> <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: IM, IV: 1,000 mg/m<sup>2</sup>/day <b>or</b> 25 to 50 mg/kg/day for 5 days; a maximum dose of 3,000 mg has been suggested (Howland 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lead encephalopathy (in conjunction with dimercaprol):</i> <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: IM, IV: 1,500 mg/m<sup>2</sup>/day <b>or</b> 50 to 75 mg/kg/day for 5 days; a maximum dose of 3,000 mg has been suggested (Howland 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lead nephropathy:</i> An alternative dosing regimen reflecting the reduction in renal clearance is based upon the serum creatinine; <b>Note:</b> Repeat regimen monthly until lead levels are reduced to an acceptable level: IM, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> 2 to 3 mg/dL: 500 mg/m<sup>2</sup> every 24 hours for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> 3 to 4 mg/dL: 500 mg/m<sup>2</sup> every 48 hours for 3 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">S<sub>cr</sub> &gt;4 mg/dL: 500 mg/m<sup>2</sup> once weekly</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164149\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=edetate-calcium-disodium-calcium-edta-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Edetate calcium disodium (calcium EDTA): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Lead poisoning:</b> <b>Note:</b> For the treatment of high blood lead levels in children, the CDC recommends chelation treatment when blood lead levels are &gt;45 mcg/dL (CDC 2002). The AAP recommends succimer as the drug of choice for the initial management in asymptomatic children when blood lead levels are &gt;45 mcg/dL and &lt;70 mcg/dL. Edetate CALCIUM disodium can be used in children allergic to succimer (AAP 2005; Chandran 2010). Combination therapy with edetate CALCIUM disodium and dimercaprol is recommended for use in children whose blood lead levels are &ge;70 mcg/dL or in children with lead encephalopathy (AAP 2005; Chandran 2010). Depending upon the blood lead level, additional courses may be necessary; at least 2 to 4 days should elapse before repeat treatment is initiated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Blood lead levels &lt;70 mcg/dL and asymptomatic:</i> IM, IV: 1,000 mg/m<sup>2</sup>/day for 5 days or 50 mg/kg/day (maximum: 1,000 mg/day) for 5 days (Chandran 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Blood lead levels &ge;70 mcg/dL or symptomatic lead poisoning (in conjunction with dimercaprol):</i> <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: IM, IV: 1,000 mg/m<sup>2</sup>/day <b>or</b> 25 to 50 mg/kg/day (maximum: 1,000 mg/day) for 5 days (Chandran 2010; Howland 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lead encephalopathy (in conjunction with dimercaprol):</i> <b>Note:</b> Begin treatment with edetate CALCIUM disodium with the second dimercaprol dose: IM, IV: 1,500 mg/m<sup>2</sup>/day <b>or</b> 50 to 75 mg/kg/day (maximum: 1,000 mg/day) for 5 days (Chandran 2010; Howland 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164146\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6151791\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Dose should be reduced with preexisting mild renal disease. Limiting the daily dose to 1 g in children and 2 g in adults may decrease risk of nephrotoxicity, although larger doses may be needed in the treatment of lead encephalopathy (Howland 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164129\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/5 mL (5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164114\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164131\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For IM or IV use; IV is generally preferred, however, the IM route is preferred when cerebral edema is present.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion: Administer the daily dose as a diluted solution over 8 to 12 hours or continuously over 24 hours (Howland 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">For IM injection: Daily dose should be divided into 2 to 3 equal doses spaced 8 to 12 hours apart. Procaine hydrochloride or lidocaine may be added to the edetate CALCIUM disodium to minimize pain at injection site. Administer by deep IM injection. When used in conjunction with dimercaprol, inject into a separate site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164130\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of symptomatic acute and chronic lead poisoning</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2932700\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">To avoid potentially serious errors, the abbreviation &ldquo;EDTA&rdquo; should <b>never</b> be used.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na<sub>2</sub>EDTA) (not commercially available in the U.S. or Canada). CDC recommends that edetate disodium should <b>never</b> be used for chelation therapy in children. Fatal hypocalcemia may result if edetate disodium is used for chelation therapy instead of edetate calcium disodium. ISMP recommends confirming the diagnosis to help distinguish between the two drugs prior to dispensing and/or administering either drug.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;text-align:justify;\">Edetate CALCIUM disodium may be confused with etomidate</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164121\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia, ECG changes, hypotension, local thrombophlebitis (IV infusion when concentration &gt;5 mg/mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Chills, fatigue, headache, malaise, numbness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Cheilosis, dermatitis, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Glycosuria, hypercalcemia, hypokalemia, iron deficiency (with chronic therapy), magnesium deficiency (with chronic therapy), polydipsia, zinc deficiency (with chronic therapy) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Anorexia, gastrointestinal irritation, nausea, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Nephrosis, nephrotoxicity, occult blood in urine, proteinuria, urinary frequency, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, bone marrow depression (transient) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Decreased serum alkaline phosphatase, increased liver enzymes (mild) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Pain at injection site (intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Lacrimation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Nasal congestion, sneezing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164134\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Active renal disease or anuria; hepatitis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164118\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Monitor for arrhythmias and ECG changes during IV therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Edetate CALCIUM disodium is potentially nephrotoxic. Renal tubular acidosis and fatal nephrosis may occur, especially with high doses; do not exceed the recommended daily dose. If anuria, increasing proteinuria, or hematuria occurs during therapy, discontinue use. Minimize nephrotoxicity by providing adequate hydration, establishment of good urine output, avoidance of excessive doses, and limit continuous administration to &le;5 days.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebral edema: <b>[US Boxed Warning]: Use with extreme caution in patients with lead encephalopathy and cerebral edema.</b> In these patients, IV infusion has been associated with a lethal increase in intracranial pressure; IM injection is preferred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lead poisoning: Investigate, identify, and remove sources of lead exposure prior to treatment. Primary care providers should consult experts in chemotherapy of lead toxicity before using chelation drug therapy. Do not permit patients to re-enter the contaminated environment until lead abatement has been completed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; reduced dose recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Potential for name confusion: Exercise caution in the ordering, dispensing, and administration of this drug. Edetate CALCIUM disodium (CaEDTA) may be confused with edetate disodium (Na<sub>2</sub>EDTA) (not commercially available in the US or Canada). Fatal hypocalcemia may result if edetate disodium is used for the treatment of lead poisoning instead of edetate CALCIUM disodium (Baxter 2008). The CDC and FDA recommend that edetate disodium should never be used for chelation therapy (especially in children) (Mitka 2008). Death has occurred following the use of edetate disodium for chelation therapy in pediatric patients with autism (Baxter 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299251\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220072\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9401&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Edetate CALCIUM Disodium may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164125\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6151785\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies; there are no well controlled studies of edetate CALCIUM disodium in pregnant women. Lead is known to cross the placenta in amounts related to maternal plasma levels.  Prenatal lead exposure may be associated with adverse events such as spontaneous abortion, preterm delivery, decreased birth weight, and impaired neurodevelopment.  Some adverse outcomes may occur with maternal blood lead levels &lt;10 mcg/dL.  In addition, pregnant women exposed to lead may have an increased risk of gestational hypertension. Consider chelation therapy in pregnant women with confirmed blood lead levels &ge;45 mcg/dL (pregnant women with blood lead levels &ge;70 mcg/dL should be considered for chelation regardless of trimester). Alternatives to edetate CALCIUM disodium may be indicated and consultation with experts in lead poisoning and high-risk pregnancy is recommended.  Encephalopathic pregnant women should be chelated regardless of trimester (CDC 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6151788\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The oral absorption of edetate CALCIUM disodium is poor (&lt;5%) which would limit exposure to a nursing infant. However, edetate CALCIUM disodium is not used orally because it may increase lead absorption from the GI tract. The amount of lead in breast milk may range from 0.6% to 3% of the maternal serum concentration. Women with confirmed blood lead levels &ge;40 mcg/dL should not initiate breast-feeding; pumping and discarding breast milk is recommended until blood lead levels are &lt;40 mcg/dL, at which point breast-feeding may resume (CDC 2010).  Calcium supplementation may reduce the amount of lead in breast milk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164127\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Urinary output; urinalysis; renal function, hepatic function, serum electrolytes (baseline and daily [severe lead poisoning] or at days 2 and 5 [less severe lead poisoning]); ECG (with IV therapy); blood lead levels (baseline and 7-21 days after completing chelation therapy); hemoglobin or hematocrit; iron status; free erythrocyte protoporphyrin or zinc protoporphyrin; neurodevelopmental changes </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164117\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Calcium is displaced by divalent and trivalent heavy metals, forming a nonionizing soluble complex with lead that is excreted in the urine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164133\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Chelation of lead: IV: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maximum excretion of chelated lead with IV administration: 24 to 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ: Well absorbed; Oral: &lt;5%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Into extracellular fluid; minimal CSF penetration (~5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Almost none of the drug is metabolized</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metal chelates or unchanged drug); decreased GFR decreases elimination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038608\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Calcium Disodium Versenate (AU);</li>\n      <li>Calcium Edetate de Sodium (FR);</li>\n      <li>Edetal-CA (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Environmental Health, &ldquo;Lead Exposure in Children: Prevention, Detection, and Management,&rdquo; <i>Pediatrics</i>, 2005, 116(4):1036-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/16199720/pubmed\" target=\"_blank\" id=\"16199720\">16199720</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baxter AJ and Krenzelok EP, &ldquo;Pediatric Fatality Secondary to &lsquo;EDTA&rsquo; Chelation Therapy for Autism,&rdquo; <i>Clin Toxicol (Phila)</i>, 2008, 46(10):1083-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/18949650/pubmed\" target=\"_blank\" id=\"18949650\">18949650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradberry S and Vale A, &ldquo;A Comparison of Sodium Calcium Edetate (Edetate Calcium Disodium) and Succimer (DMSA) in the Treatment of Inorganic Lead Poisoning,&rdquo; <i>Clin Toxicol (Phila)</i>, 2009, 47(9):841-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/19852620/pubmed\" target=\"_blank\" id=\"19852620\">19852620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calcium disodium versenate (edetate calcium disodium) [prescribing information]. Bristol, TN: Luitpold Pharmaceuticals, Inc; July 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Deaths Associated With Hypocalcemia From Chelation Therapy --Texas, Pennsylvania, and Oregon, 2003-2005,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2006, 55(8):204-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/16511441/pubmed\" target=\"_blank\" id=\"16511441\">16511441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevetion (CDC), <i>Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women</i>, Atlanta: CDC; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), <i>Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention</i>, Atlanta: CDC; 2002.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Interpreting and Managing Blood Lead Levels &lt;10 microg/dL in Children and Reducing Childhood Exposures to Lead: Recommendations of CDC's Advisory Committee on Childhood Lead Poisoning Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 2007, 56(RR-8):1-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/17975528/pubmed\" target=\"_blank\" id=\"17975528\">17975528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chandran L and Cataldo R, &ldquo;Lead Poisoning: Basics and New Developments,&rdquo; <i>Pediatr Rev</i>, 2010, 31(10):399-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/20889734/pubmed\" target=\"_blank\" id=\"20889734\">20889734</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gracia RC and Snodgrass WR, &ldquo;Lead Toxicity and Chelation Therapy,&rdquo; <i>Am J Health Syst Pharm</i>, 2007, 64(1):45-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/17189579 /pubmed\" target=\"_blank\" id=\"17189579 \">17189579 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland M, &ldquo;Antidotes in Depth: Edetate Calcium Disodium (CaNa2EDTA),&rdquo; <i>Goldfrank's Toxicologic Emergencies</i>, 9th ed, Nelson LS, Hoffman RS, Lewin NA, et al, eds, New York, NY: McGraw-Hill Companies, Inc, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Howland M. Antidotes in depth: edetate calcium disodium (CaNa2EDTA). <i>Goldfrank's Toxicologic Emergencies.</i> 10th ed. Hoffman RS, Howland MA, Lewin NA, et al, eds. New York, NY: McGraw-Hill Companies, Inc; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kosnett MJ, Wedeen RP, Rothenberg SJ, et al, &ldquo;Recommendations for Medical Management of Adult Lead Exposure,&rdquo; <i>Environ Health Perspect</i>, 2007, 115(3):463-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/17431500/pubmed\" target=\"_blank\" id=\"17431500\">17431500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitka M, &ldquo;Chelation Therapy Trials Halted,&rdquo; <i>JAMA</i>, 2008, 300(19):2236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/19017902/pubmed\" target=\"_blank\" id=\"19017902\">19017902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moel DI and Kumar K, &ldquo;Reversible Nephrotic Reactions to a Combined 2,3-Dimercapto-1-propanol and Calcium Disodium Ethylenediaminetetraacetic Acid Regimen in Asymptomatic Children With Elevated Blood Lead Levels,&rdquo; <i>Pediatrics</i>, 1982, 70(2):259-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/7099793/pubmed\" target=\"_blank\" id=\"7099793\">7099793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan JM, &ldquo;Chelation Therapy in Lead Nephropathy,&rdquo; <i>South Med J</i>, 1975, 68(8):1001-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/125923/pubmed\" target=\"_blank\" id=\"125923\">125923</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osterloh J and Becker CE, &ldquo;Pharmacokinetics of CaNa<sub>2</sub> EDTA and Chelation of Lead in Renal Failure,&rdquo; <i>Clin Pharmacol Ther</i>, 1986, 40(6):686-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edetate-calcium-disodium-calcium-edta-drug-information/abstract-text/3096624/pubmed\" target=\"_blank\" id=\"3096624\">3096624</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9401 Version 97.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708725\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F164152\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F164145\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F164149\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F164146\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6151791\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164129\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F164114\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F164131\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F164130\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2932700\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164121\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164134\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164118\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299251\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220072\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F164125\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6151785\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6151788\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F164127\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164117\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F164133\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038608\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9401|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=edetate-calcium-disodium-calcium-edta-patient-drug-information\" class=\"drug drug_patient\">Edetate calcium disodium (calcium EDTA): Patient drug information</a></li><li><a href=\"topic.htm?path=edetate-calcium-disodium-calcium-edta-pediatric-drug-information\" class=\"drug drug_pediatric\">Edetate calcium disodium (calcium EDTA): Pediatric drug information</a></li></ul></div></div>","javascript":null}